sb 203580 has been researched along with benzofurans in 2 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (benzofurans) | Trials (benzofurans) | Recent Studies (post-2010) (benzofurans) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 13,293 | 451 | 4,970 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, W; Han, HJ; Jeon, YJ; Kim, HS; Lee, MY; Park, SH; Song, KS | 1 |
Abdel-Ghani, TM; Ali, HI; Amin, KM; Anwar, MM; Serry, AM; Syam, YM | 1 |
2 other study(ies) available for sb 203580 and benzofurans
Article | Year |
---|---|
Protective effect of dieckol against chemical hypoxia-induced cytotoxicity in primary cultured mouse hepatocytes.
Topics: Animals; Benzofurans; Cell Hypoxia; Cell Survival; Cells, Cultured; Cobalt; Cyclooxygenase 2; Dose-Response Relationship, Drug; Hepatocytes; Imidazoles; Male; Mice; Mice, Inbred ICR; Nitrobenzenes; p38 Mitogen-Activated Protein Kinases; Pyridines; Reactive Oxygen Species; Sulfonamides; Time Factors | 2015 |
Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Breast Neoplasms; Caspase 3; Caspase 9; Catalytic Domain; Chromones; Doxorubicin; G2 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MCF-7 Cells; Mitogen-Activated Protein Kinase 14; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyridines | 2018 |